health canada approval zepbound tirzepatide obesity canada 2024 2025 A 72-week trial compared the two leading GLP-1 medications in adults with (no diabetes). The results: ✓ Tirzepatide: 20.2% weight loss ✓ Semaglutide: 13.7% weight loss But weight loss isn't the GLP-1 Drugs Market Size to

Mounjaro is suitable for adults with: A BMI of 30 or over (obesity) A BMI of 27 or over (overweight) and at least one weight-related health issue like prediabetes, high blood pressure, high cholesterol, or heart problems

Forecasting models often overestimate ROI: Many commercial forecasts fail to account for patient leakage, especially in obesity indications, leading to inflated expectations and missed market realities

each kidney has approximately 1 million of these independently functioning units (Baynes 2014)

Herbal supplements can be especially dodgy when it comes to issues with contamination, says Nicholas Milazzo, the lead researcher at nutrition and supplement database Examine.com